<DOC>
	<DOCNO>NCT00056004</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use zileuton may effective way prevent lung cancer patient bronchial dysplasia . PURPOSE : Randomized phase II trial study effectiveness zileuton prevent lung cancer patient bronchial dysplasia .</brief_summary>
	<brief_title>Zileuton Preventing Lung Cancer Patients With Bronchial Dysplasia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy zileuton , term number site grade dysplastic lesion bronchial epithelium , patient document bronchial dysplasia . - Correlate regression bronchial dysplasia ( number grade ) improvement sputum cytology modulation molecular biomarkers patient treated drug . - Determine overall toxicity drug patient . - Determine 6-month natural history bronchial dysplasia patient randomize receive treatment placebo . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord smoking status ( current v recently quit smoker ) , prior cancer ( none v lung head neck ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral zileuton 4 time daily 6 month absence disease progression unacceptable toxicity . - Arm II : Patients receive oral placebo 4 time daily 6 month absence disease progression unacceptable toxicity . Patients follow 4 week . PROJECTED ACCRUAL : Approximately 134 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Zileuton</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At high risk dysplasia , define 1 follow criterion : Current former smoker smoke least 30 packyears Former smoker must enrol within 20 year complete smoke cessation Patients curatively treated stage I nonsmall cell lung cancer* Patients curatively treat stage I II squamous cell carcinoma head neck ( limited oral cavity , pharynx , larynx ) * NOTE : *At least 12 month postcurative therapy Histologic confirmation mild severe bronchial dysplasia bronchoscopic biopsy require Moderate severe atypia sputum cytology require bronchoscopy ( required patient prior lung head neck cancer ) No evidence malignancy chest xray PATIENT CHARACTERISTICS : Age 18 ( patient prior lung head neck malignancy ) 35 ( patient ) Performance status SWOG 01 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10.0 g/dL No bleeding disorder Hepatic Bilirubin great upper limit normal ( ULN ) Liver enzymes great ULN PT/PTT great ULN No active chronic liver disease ( even transaminases normalize ) Renal Creatinine great ULN Cardiovascular No unstable angina No uncontrolled heart failure Pulmonary No significant asthma chronic obstructive pulmonary disease require chronic periodic ( least per year ) steroids flare No acute chronic respiratory failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing able undergo serial bronchoscopic examination No ongoing alcohol use ( i.e. , least 1 glass wine , beer , mixed drink per day regular basis ) No medical condition would preclude safety study participation No active invasive malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No hypersensitivity study drug inactive ingredient PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 3 month since prior corticosteroids* No concurrent corticosteroids* No concurrent anticancer hormonal agent NOTE : *Systemic inhaled , include chronic administration Radiotherapy No concurrent radiotherapy Surgery Not specify Other More 3 month since prior lipoxygenase inhibitors* More 3 month since prior investigational agent More 3 month since prior nutritional supplement ( except 1 daily multivitamin ) No concurrent nutritional supplement ( except 1 daily multivitamin ) No concurrent lipoxygenase inhibitors* No concurrent investigational agent No concurrent warfarin , betablockers , theophylline No concurrent antineoplastic agent No concurrent chronic daily use nonsteroidal antiinflammatory agent ( NSAIDS ) ( except cardioprotective dos aspirin less 100 mg/day ) Periodic use NSAIDS allow Concurrent participation smoke cessation program ( include use bupropion nicotine gum patch ) allow NOTE : *Systemic inhale , include chronic administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
</DOC>